1-[2-(3-Pyrrolidin-1-ylprop-1-ynyl)pyrrolidin-1-yl]ethanone | 118800-07-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-[2-(3-Pyrrolidin-1-ylprop-1-ynyl)pyrrolidin-1-yl]ethanone
• CAS: 118800-07-0
• 化学式: C₁₃H₂₀N₂O
• 分子量: 220.315
• InChiKey: JNDOCQKNQCJTBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  四氢吡咯 、 聚合甲醛 、 alkaline earth salt of/the/ methylsulfuric acid 在 copper(l) chloride 作用下， 以 1,4-二氧六环 、 溶剂黄146 为溶剂， 反应 24.0h， 生成 1-[2-(3-Pyrrolidin-1-ylprop-1-ynyl)pyrrolidin-1-yl]ethanone
  参考文献：
  名称：

  Conformationally restricted analogs of the muscarinic agent N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide

  摘要：

  Conformationally restricted analogues of the selective partial muscarinic agonist N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM 5; 2) were synthesized. The compounds were tested for muscarinic and antimuscarinic activity in the isolated guinea pig ileum and in intact mice. They were found to be moderately potent muscarinic antagonists or weak partial agonists. The new compounds were less potent than 2 in inhibiting (-)-[3H]-N-methylscopolamine binding in the rate cerebral cortex. Thus, structural modifications of 2 in which part of the amide moiety has been connected with the methyl group in the butynyl chain to form a five-membered ring decrease affinity and in most cases abolish efficacy.

  DOI：

  10.1021/jm00124a022

文献信息

• 1-Substituted-2-(3-amino-1-propynyl)-pyrrolidine derivatives
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0408879A2

  公开（公告）日：1991-01-23

  Compounds of the formula: pharmaceutical compositions containing the compounds and methods of using the compounds in the treatment of central cholinergic disfuction in a mammal are disclosed.

  式的化合物： 公开了含有这些化合物的药物组合物以及使用这些化合物治疗哺乳动物中枢胆碱能失调的方法。
• Heterocyclic acetylenic amines having central nervous system activity
  申请人：THE UPJOHN COMPANY

  公开号：EP0605393A1

  公开（公告）日：1994-07-06

  Compounds of formula I have cholinergic agonist or antagonist activity useful in the treatment of mental disorders, extrapyramidal motor disorders, disorders of the parasympathetic nervous system and glaucoma or as analgesics for the treatment of pain. Typical central nervous system disorders for which the subject compounds can be used include cognitive disorders of all ages, including senile dementia, Alzheimer's disease and other related disorders. The compounds are particularly developed to improve mental performance when a mental deficiency is diagnosed.

  式 I 的化合物 具有胆碱能激动剂或拮抗剂活性，可用于治疗精神障碍、锥体外系运动障碍、副交感神经系统紊乱和青光眼，或用作治疗疼痛的镇痛剂。有关化合物可用于治疗的典型中枢神经系统疾病包括所有年龄段的认知障碍，包括老年痴呆症、阿尔茨海默病和其他相关疾病。特别是在诊断出精神缺陷时，这些化合物可用于改善精神状态。
• HETEROCYCLIC ACETYLENIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY
  申请人：THE UPJOHN COMPANY

  公开号：EP0440670A1

  公开（公告）日：1991-08-14
• US5001142A
  申请人：——

  公开号：US5001142A

  公开（公告）日：1991-03-19
• US5128483A
  申请人：——

  公开号：US5128483A

  公开（公告）日：1992-07-07